JAZZ
Jazz Pharmaceuticals plc · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -5.6% ·
share flow +3.4% ·
net new positions -5.9%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 23.86K | $4.65M | +1 | −1 |
| Q2 2026 | 135 | +4 | 47.42M | $11.41B | +7 | −4 |
| Q1 2026 | 135 | -10 | 49.63M | $8.67B | +4 | −14 |
| Q4 2025 | 144 | +2 | 48.56M | $7.62B | +2 | n/a |
| Q3 2025 | 20 | 0 | 25.68M | $3.38B | +1 | −1 |
| Q2 2025 | 17 | -1 | 21.49M | $2.28B | +1 | −2 |
| Q1 2025 | 15 | 0 | 8.34M | $1.04B | +1 | −1 |
| Q4 2024 | 15 | 0 | 8.56M | $1.05B | +1 | −1 |
| Q3 2024 | 14 | -2 | 7.38M | $822.21M | n/a | −2 |
| Q2 2024 | 16 | n/a | 7.74M | $826.28M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 6.09M | n/a | $646.36M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 5.80M | n/a | $615.47M | 0.0% | n/c | 1 | SEC ↗ ×20 |
| 3 | Capital World Investors ✦ | 2.54M | +32.0% | $270.02M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passive) | 1.94M | -1.6% | $205.38M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 5 | Geode Capital Management ✦ (passive) | 1.17M | +1.4% | $124.37M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | Renaissance Technologies ✦ | 900.37K | -13.8% | $95.55M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 794.77K | +62.1% | $84.34M | 0.1% | ▲ Add | 5 | SEC ↗ ×4 |
| 8 | Millennium Management ✦ | 661.70K | +2985.3% | $70.22M | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 9 | Citadel Advisors ✦ | 622.17K | -10.7% | $66.02M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 10 | Fidelity (FMR) ✦ | 547.53K | n/a | $58.10M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 11 | Adage Capital Partners ✦ | 135.04K | +938.8% | $14.33M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Wellington Management ✦ | 119.39K | +18.2% | $12.67M | 0.0% | ▲ Add | 5 | SEC ↗ ×6 |
| 13 | Gotham Asset Management ✦ | 68.47K | +35.9% | $7.27M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 45.11K | -86.9% | $4.79M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 15 | T. Rowe Price ✦ | 44.06K | +3.8% | $4.68M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 16 | Marshall Wace ✦ | 6.58K | New | $698,057 | 0.0% | New | 1 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 3.91K | -94.1% | $414,505 | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $698,057 | 0.0% |
Exited
| Bridgewater Associates | $31.16M | was 0.1% |
| Point72 Asset Management | $21.59M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 568 holders, 63.82M shares, $11.28B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 2.00K sh · $472,800
Director · 6.00K sh · $1.38M
Officer · 1.20K sh · $289,128
Officer · 2.00K sh · $486,060
Director · 6.00K sh · $1.50M
Officer · 300 sh · $75,828
Officer · 18.11K sh · $4.53M
Officer · 9.26K sh · $2.33M
Officer · 11.42K sh · $2.84M
Officer · 18.19K sh · $4.51M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology